CV Healthcare

CapsoVision, Inc.

$6.70-0.45%

Price as of close on Nov 3, 2026 · Financials updated Oct 8, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 356.5M USD
Enterprise value: 327.4M USD
Full-time employees: 99

Overall health

Strength: lower risk than most peers: less debt relative to equitylower risk: less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #949 of 1,157 healthcare companies (bottom 19%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, CapsoVision looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
CapsoVision reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

32/ 100

Oct 5 32 → Nov 4 32

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-8.9%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-9.0%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-8.3%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield3.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

38/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▲ Stronger

12-month revenue up 2.4%

Why

Weaker than most peers on:

▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0584 · MAD: 0.0840

Revenue growth11.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.50Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-217.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -18.42Sector median: 0.0706 · MAD: 0.1217

Return on assets-160.6%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-180.9%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin50.9%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-226.6%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio3.35×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.55Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.05×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.83Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about CapsoVision

Is CapsoVision getting weaker?: Its latest SEC filing (Aug 13, 2026) showed no major changes. Its overall score is unchanged at 32/100 since Oct 28, 2026.
How is CapsoVision valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -8.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.9% vs peers 1.5% (weaker than 100% of peers).
Is CapsoVision growing?: More slowly than most of its peers. Growth scores 38/100 against 1,393 healthcare peers. Revenue growth 11.0% vs a peer median of 6.1% (stronger than 63% of peers).Revenue growth 11.0% vs peers 6.1% (stronger than 63% of peers).
How profitable is CapsoVision?: Less profitable than most of its peers. Profitability scores 8/100 against 1,393 healthcare peers. Return on assets -160.6% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -160.6% vs peers 1.7% (weaker than 100% of peers).
How risky is CapsoVision?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.05× vs a peer median of 0.22× (stronger than 75% of peers).Debt / equity 0.05× vs peers 0.22× (stronger than 75% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 13, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: CapsoVision is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	13.6M USD	13.9M USD	+2.4%
Net income (12 months)	−27.0M USD	−29.8M USD	+10.6%
Operating margin	-200.7%	-217.1%	−16.3 pts
Free cash flow (12 months)	−24.0M USD	−27.9M USD	+16.0%
Shares outstanding	50.0M	50.0M	+0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2024	FY 2025	Change
Gross margin	54.2%	52.9%	▼ 1.3 pts
Operating margin	-169.4%	-188.3%	▼ 19 pts
Net margin	-169.3%	-186.8%	▼ 18 pts
Return on assets (ROA)	-118.4%	-139.4%	▼ 21 pts
Return on equity (ROE)	—	-190.9%	—
Free cash flow margin	-172.2%	-169.4%	▲ 2.8 pts
Current ratio	8.24×	3.77×	▼ 54%
Quick ratio	6.78×	3.09×	▼ 54%

CV price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: less debt relative to equitylower risk: less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #949 of 1,157 healthcare companies (bottom 19%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, CapsoVision looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

CapsoVision reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about CapsoVision

Is CapsoVision getting weaker?

Its latest SEC filing (Aug 13, 2026) showed no major changes. Its overall score is unchanged at 32/100 since Oct 28, 2026.

How is CapsoVision valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -8.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.9% vs peers 1.5% (weaker than 100% of peers).

Is CapsoVision growing?

More slowly than most of its peers. Growth scores 38/100 against 1,393 healthcare peers. Revenue growth 11.0% vs a peer median of 6.1% (stronger than 63% of peers).Revenue growth 11.0% vs peers 6.1% (stronger than 63% of peers).

How profitable is CapsoVision?

Less profitable than most of its peers. Profitability scores 8/100 against 1,393 healthcare peers. Return on assets -160.6% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -160.6% vs peers 1.7% (weaker than 100% of peers).

How risky is CapsoVision?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.05× vs a peer median of 0.22× (stronger than 75% of peers).Debt / equity 0.05× vs peers 0.22× (stronger than 75% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

13.6M USD

13.9M USD

+2.4%

Net income (12 months)

−27.0M USD

−29.8M USD

+10.6%

Operating margin

-200.7%

-217.1%

−16.3 pts

Free cash flow (12 months)

−24.0M USD

−27.9M USD

+16.0%

Shares outstanding

50.0M

50.0M

+0.2%

Key ratios

FY 2024

FY 2025

Change

Gross margin

54.2%

52.9%

▼ 1.3 pts

Operating margin

-169.4%

-188.3%

▼ 19 pts

Net margin

-169.3%

-186.8%

▼ 18 pts

Return on assets (ROA)

-118.4%

-139.4%

▼ 21 pts

Return on equity (ROE)

—

-190.9%

—

Free cash flow margin

-172.2%

-169.4%

▲ 2.8 pts

Current ratio

8.24×

3.77×

▼ 54%

Quick ratio

6.78×

3.09×

▼ 54%